New
Service for TodaysSeniorsNetwork.com
readers...roll mouse over, click on
highlighted links in stories to review items
from Amazon
Now, keep up to date
with daily feeds of newly posted stories
about America's Seniors...click on the box
to the left
Women are
treated less frequently than men with
Statins, Aspirin and Beta- Blockers
Newswise — Women and
men experience a similar prevalence of
adverse drug reactions in the treatment of
coronary artery disease; however, women are
significantly less likely than their male
counterparts to be treated with statins,
aspirin, and beta-blockers according to a
new study by researchers at Rush University
Medical Center.
The study is published in
the March issue of the journal Gender
Medicine.
“Developments in
disease recognition and novel treatment
strategies have led to a significant decline
in overall cardiovascular death rate among
men, but these dramatic improvements have
not been observed in women,” said Dr.
Jonathan R. Enriquez, lead author of the
study and resident internal medicine
physician at Rush.
“This may be related to
underutilization of medical therapies such
as aspirin, ß-blockers, ACE inhibitors or statins.”
In association with Dr.
Annabelle Volgman and the Rush Heart Center
for Women, the study involved 304
consecutive patients with coronary artery
disease at the outpatient cardiology clinic
at Rush.
A retrospective observational
analysis was performed to determine the
usage and adverse reactions reported from
aspirin, ß-blockers, angiotensin-converting-enzyme
(ACE) inhibitors or statins.
Baseline
clinical characteristics were also
determined to identify the independent
association of gender on usage of standard
medical coronary artery disease treatments.
The study found that
only 78.1 percent of women were treated with
statins compared to 90.8 percent of men.
After adjustment for clinical
characteristics, men were also found to be
six times more likely to receive aspirin and
beta-blockers. No significant difference was
noted between genders in the prevalence of
adverse drug reactions.
“The physician’s
perception of either anticipated adverse
drug reactions or less severe disease may be
influencing their decision to not prescribe
these medications for women,” said Enriquez.
“We encourage further studies to identify
the cause of this disparity, so that care
for women with coronary artery disease may
be optimized.”
Coronary artery disease
is the leading-cause of death among women in
the United States and annually since 1984
the number of cardiovascular-related deaths
in women has exceeded that of men.
Women may
not only suffer from decreased survival with
coronary artery disease, but may also
experience a worse quality of life than men.
“Given the findings of
this study and other studies documenting the
underutilization of current medical
therapies in women, we must consider
potential solutions to improve care of all
patients during the outpatient visit,” said
Enriquez.
At the Rush Heart
Center for Women, women with heart problems
are diagnosed and treated with great
sensitivity and innovation by a team of
cardiologists, nurse practitioners, nurses,
nutritionists and cardiothoracic surgeons
who are supported by the comprehensive
resources of a world-class academic medical
center.
Women without overt heart disease
are assessed and advised on how to prevent
heart disease and stroke.
Rush University Medical
Center is an academic medical center that
encompasses the more than 600 staffed-bed
hospital (including Rush Children’s
Hospital), the Johnston R. Bowman Health
Center and Rush University.
Rush University,
with more than 1,270 students, is home to
one of the first medical schools in the
Midwest, and one of the nation’s top-ranked
nursing colleges.
Rush University also
offers graduate programs in allied health
and the basic sciences.
Rush is noted for
bringing together clinical care and research
to address major health problems, including
arthritis and orthopedic disorders, cancer,
heart disease, mental illness, neurological
disorders and diseases associated with
aging.
...
...
...